Drug intelligence / Profile preview

morphine + memantine

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

The combination of morphine and memantine is an investigational approach where memantine (an NMDA receptor antagonist) is used as an adjunct to morphine (an opioid analgesic) therapy. Research suggests that low-dose memantine may attenuate morphine addiction behavior through anti-inflammatory and neurotrophic effects. This combination may also enhance pain management while potentially allowing for reduced opioid dosages in chronic pain patients.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on morphine + memantine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on morphine + memantine.

Explore the full profile